🔍

ACUTAAS - Acutaas Chemical

📊 NSE: ACUTAAS 🏢 Pharmaceuticals 📅 Last Updated: 11/13/2025 15:25

📢 Recent Corporate Announcements

Acutaas Chemicals Releases Earnings Call Recording for April 30, 2026

🟡 NEUTRAL ⭐ 3/10

EARNINGS 📅 30 Apr 2026, 07:18 PM

Acutaas Chemicals Limited has made the audio recording of its earnings conference call held on April 30, 2026, available to the public. This disclosure follows the company's initial intimation on April 27, 2026, and complies with SEBI Listing Obligations and Disclosure Requirements. The recording provides management's perspective on the recent financial performance and future outlook. Investors can access the file directly via the company's investor relations portal or the provided URL.

Earnings call conducted on April 30, 2026, at 5:30 p.m. IST.
Compliance with SEBI LODR Regulations 30 and 46(2) regarding transparency.
Recording link hosted at https://backend.acutaas.com/resources/investor/recording-1777555736851.mp3.
Follow-up to the prior notification submitted to exchanges on April 27, 2026.

💡 Investors should listen to the recording to understand management's commentary on business growth and operational challenges. This is a routine but essential step for due diligence following quarterly results.

Acutaas Chemicals Recommends Final Dividend of Rs 2.5 Per Share for FY 2025-26

🟢 POSITIVE ⭐ 7/10

DIVIDEND 📅 30 Apr 2026, 05:37 PM

The Board of Directors of Acutaas Chemicals Limited has recommended a final dividend of Rs 2.5 per equity share for the financial year 2025-26. This represents a 50% payout on the face value of Rs 5 per share. The dividend will be distributed across 8,18,71,122 equity shares, pending approval from shareholders at the upcoming 19th Annual General Meeting. Record and payout dates will be announced by the company in due course.

Recommended a final dividend of Rs 2.5 per equity share for FY 2025-26
Dividend rate stands at 50% of the face value of Rs 5 per share
Total number of eligible equity shares is 8,18,71,122
Subject to shareholder confirmation at the 19th Annual General Meeting

💡 Investors should hold the stock to be eligible for the dividend and watch for the announcement of the record date. The 50% dividend payout reflects a positive return to shareholders for the fiscal year.

Acutaas Chemicals FY26 PAT Surges 122% to ₹3,564 Mn; Q4 Margins Hit Record 31%

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 30 Apr 2026, 12:47 PM

Acutaas Chemicals (formerly Ami Organics) delivered exceptional FY26 results, with annual revenue rising 33% to ₹13,394 million. Net profit for the year surged 122% to ₹3,564 million, supported by a massive expansion in EBITDA margins to 35.9%. The company achieved its highest-ever quarterly PAT margin of 31% in Q4 FY26, driven by strong growth in the Pharma CDMO and Semiconductor businesses. Management has guided for a robust 25% revenue growth in FY27, focusing on high-growth verticals like battery chemicals.

FY26 Revenue grew 33% YoY to ₹13,394 million, led by a 37.5% jump in Advance Intermediates.
Annual PAT surged 122.2% to ₹3,564 million, while Q4 PAT rose 114.1% YoY to ₹1,343 million.
EBITDA margins expanded significantly from 23.0% in FY25 to 35.9% in FY26.
Return on Equity (ROE) jumped to 32.5% in FY26 compared to 15.1% in the previous year.
Management provided a strong growth outlook of 25% revenue increase for FY27.

💡 The company demonstrates industry-leading margin expansion and high return ratios (ROCE of 39.3%). Investors should monitor the execution of the 25% growth guidance for FY27 as a key performance indicator.

Acutaas Chemicals Q4 PAT Surges 114% YoY to ₹1,343 Mn; FY27 Revenue Guidance at 25%

🟢 POSITIVE ⭐ 9/10

EARNINGS 📅 30 Apr 2026, 12:38 PM

Acutaas Chemicals reported a stellar performance for Q4 FY26, with revenue growing 40.3% YoY to ₹4,328 million. Net profit (PAT) more than doubled, rising 114.1% YoY to ₹1,343 million, driven by significant margin expansion. EBITDA margins improved drastically to 42.4% from 27.5% in the previous year's quarter. For the full year FY26, the company achieved a PAT of ₹3,564 million, a 122.2% increase over FY25. Management has provided a confident outlook, guiding for 25% revenue growth in FY27.

Q4 FY26 Revenue from operations grew 40.3% YoY to ₹4,328 million
Q4 PAT jumped 114.1% YoY to ₹1,343 million with record margins of 31.0%
EBITDA for the quarter rose 116% YoY to ₹1,835 million, with margins expanding to 42.4%
Full-year FY26 PAT reached ₹3,564 million, marking a 122.2% growth over FY25
Management guided for 25% revenue growth in FY27, focusing on Battery Chemicals and Semiconductors

💡 Investors should consider the stock's strong momentum and margin expansion as a sign of successful diversification into high-value sectors. The 25% growth guidance for FY27 provides clear visibility for future earnings and justifies a positive outlook.

Acutaas Chemicals Recommends Rs 2.50 Dividend; Indichem INC Named Material Subsidiary

🟢 POSITIVE ⭐ 7/10

BOARD_MEETING 📅 30 Apr 2026, 12:23 PM

Acutaas Chemicals Limited (formerly Ami Organics) has approved its audited financial results for the fiscal year ended March 31, 2026. The Board recommended a final dividend of Rs 2.50 per equity share (50% of face value), pending shareholder approval. A significant development is the classification of step-down subsidiary Indichem INC as a 'Material Subsidiary' based on its financial performance. The company also refreshed its audit team by appointing new internal and cost auditors for the 2026-27 fiscal year.

Recommended a final dividend of Rs 2.50 per equity share of Rs 5 face value (50% payout).
Dividend to be distributed across 8,18,71,122 equity shares subject to AGM approval.
Indichem INC identified as a Material Subsidiary, indicating a significant contribution to consolidated financials.
M/s K. C Mehta & Co. LLP appointed as Internal Auditors for the financial year 2026-27.
Audited Standalone and Consolidated Financial Results for FY 2025-26 approved by the Board.

💡 Investors should note the dividend yield and the growing importance of the US-based subsidiary Indichem INC. Monitor the full financial statement for specific revenue and profit growth figures compared to the previous year.

Acutaas Chemicals Submits SEBI Reg 74(5) Compliance Certificate for Q4 FY2026

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 02 Apr 2026, 06:09 PM

Acutaas Chemicals Limited has submitted its quarterly compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018. The certificate, issued by the Registrar and Share Transfer Agent MUFG Intime India Private Limited, covers the quarter ended March 31, 2026. It confirms that no requests for dematerialization of securities were received, confirmed, or rejected during this period. This is a standard administrative filing required by Indian market regulators to ensure share registry integrity.

Compliance certificate submitted for the quarter ended March 31, 2026
Registrar MUFG Intime India Private Limited confirmed zero dematerialization requests were received
No security certificates were mutilated or cancelled during the reporting period
The filing adheres to mandatory SEBI (Depositories and Participants) Regulations, 2018

💡 No action is required as this is a routine regulatory disclosure. Investors should continue to monitor the company for upcoming full-year financial results.

Acutaas Chemicals to Close Trading Window from April 1, 2026, for Q4 and FY26 Results

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 25 Mar 2026, 04:19 PM

Acutaas Chemicals Limited has announced the closure of its trading window effective from April 1, 2026. This action is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, ahead of the company's audited financial results for the fourth quarter and the full financial year ending March 31, 2026. The window will remain closed for all designated persons and their immediate relatives. The trading window is scheduled to reopen 48 hours after the financial results are officially declared.

Trading window closure starts on April 1, 2026, for all designated persons.
The closure is for the consideration of audited financial results for Q4 and FY ending March 31, 2026.
Trading window will reopen 48 hours after the results are declared to the stock exchanges.
The specific date for the Board Meeting to approve the results will be announced in due course.

💡 This is a routine regulatory announcement and requires no immediate action from retail investors. Investors should monitor for the upcoming announcement of the board meeting date for the actual financial performance results.

Acutaas Chemicals to Attend Investec India Investor Conference on March 11, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 02 Mar 2026, 12:01 PM

Acutaas Chemicals Limited has announced its participation in the Investec India Promoter & Founder Conference 2026. The event is scheduled for March 11, 2026, in Mumbai, where company officials will engage in one-on-one and group meetings with institutional investors and analysts. The company has explicitly stated that no unpublished price-sensitive information (UPSI) will be discussed during these interactions. This meeting is part of the company's regular investor relations engagement following its name change from Ami Organics Limited.

Participation in Investec India Promoter & Founder Conference 2026 scheduled for March 11, 2026.
Interaction format includes both one-on-one and group meetings with analysts and investors.
Physical attendance by company officials confirmed for the Mumbai-based event.
Compliance filing under Regulation 30 of SEBI (LODR) Regulations, 2015.
Management confirmed that no unpublished price-sensitive information will be shared.

💡 Investors should monitor for any investor presentations or meeting transcripts released after the conference for updates on the company's strategic direction. No immediate action is required as this is a routine disclosure of investor engagement.

Acutaas Chemicals to Attend Investor Conferences with Ombkara Capital and Kotak in February 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 17 Feb 2026, 12:31 PM

Acutaas Chemicals Limited (formerly Ami Organics Limited) has announced its participation in two upcoming investor conferences in Mumbai. The company is scheduled to meet with Ombkara Capital on February 21, 2026, followed by the Kotak Flagship Conference 'Chasing Growth 2026' on February 24, 2026. These interactions will include both one-on-one and group meetings with institutional investors and analysts. The company has explicitly stated that no unpublished price-sensitive information (UPSI) will be discussed during these sessions.

Participation in Ombkara Capital Investors Meet scheduled for February 21, 2026.
Attendance at the Kotak Flagship Conference — Chasing Growth 2026 on February 24, 2026.
Meetings will be held in Mumbai and feature one-on-one and group interaction formats.
Management confirmed that no unpublished price-sensitive information will be shared during the meets.

💡 Investors should look for any investor presentations or transcripts that may be uploaded to the exchanges following these meetings for insights into the company's growth outlook. No immediate trading action is required as this is a routine investor relations activity.

Acutaas Chemicals Completes 75% Acquisition of South Korean Semiconductor Chemical Firm Indichem

🟢 POSITIVE ⭐ 8/10

M&A 📅 11 Feb 2026, 07:01 PM

Acutaas Chemicals, through its wholly owned subsidiary Acutaas Advance Material Limited, has completed the acquisition of a 75% controlling stake in South Korean firm Indichem Inc. Indichem is a newly incorporated entity specializing in the semiconductor chemicals industry, providing Acutaas with a strategic entry into this high-growth global market. The acquisition involved 300,000 shares at a par value of KRW 500 each plus a share premium. Indichem is currently constructing a manufacturing plant in South Korea, which is scheduled for commissioning by the end of the 2025 calendar year.

Acquired 75% controlling stake (300,000 shares) in South Korean firm Indichem Inc.
Target entity operates in the specialized semiconductor chemicals industry.
Acquisition price set at KRW 500 per share par value plus applicable share premium.
Manufacturing plant in South Korea is slated for commissioning by the end of 2025.
Indichem Inc. now becomes a step-down subsidiary of Acutaas Chemicals Limited.

💡 This acquisition is a strategic move into the high-margin semiconductor value chain. Investors should monitor the timely commissioning of the South Korean facility by late 2025 as it will be the primary driver for revenue from this new segment.

Acutaas Chemicals Q3 FY26 PAT Jumps 133.7% to ₹106.2 Cr; Revenue Guidance Raised to 30%

🟢 POSITIVE ⭐ 9/10

EARNINGS 📅 03 Feb 2026, 02:54 PM

Acutaas Chemicals reported a stellar Q3 FY26 with revenue growing 43% YoY to ₹393.2 crores, driven by a 47% surge in the Advanced Pharma Intermediates segment. The company achieved its highest-ever margins, with EBITDA margins expanding significantly to 38.3% due to a favorable product mix and operating leverage. Management has upgraded its full-year FY26 revenue growth guidance to 30% and EBITDA margin guidance to a range of 32-35%. Strategic expansions into battery and semiconductor chemicals are progressing, with a new battery chemicals block inaugurated in January 2026.

Revenue from operations grew 43% YoY to ₹393.2 crores in Q3 FY26.
PAT crossed the ₹100 crore milestone, reaching ₹106.2 crores, a 133.7% YoY increase.
EBITDA margins expanded by 1,335 bps YoY to 38.3%, leading to an upgraded annual margin guidance of 32-35%.
Pharma Intermediates segment revenue rose 47% YoY to ₹351.1 crores, fueled by CDMO growth.
Inaugurated a new battery chemicals block at Jhagadia; commercial operations expected to ramp up from Q1 FY27.

💡 Investors should view the guidance upgrade and margin expansion as strong indicators of structural growth and improved product mix. The entry into high-growth battery and semiconductor chemical segments provides a long-term catalyst for valuation re-rating.

Acutaas Chemicals Reports FY25 Revenue of ₹9,898 Million and 25% Capacity Expansion

🟢 POSITIVE ⭐ 7/10

ROUTINE 📅 29 Jan 2026, 06:29 PM

Acutaas Chemicals Limited, formerly known as Ami Organics, has released its Annual Sustainability Report for FY 2024-25, reporting a standalone revenue of ₹9,898 million. The company achieved a significant 25% increase in production capacity, primarily driven by its Ankleshwar facility. Strategically, the firm is expanding into high-value sectors including semiconductor-grade chemistries and battery materials. On the ESG front, it earned the EcoVadis Platinum Medal, placing it in the top 1% of companies globally, and operationalized 15.8 MW of solar capacity.

Standalone revenue reached ₹9,898 million with consolidated revenue surpassing ₹1,000 crore
Production capacity increased by 25% during the fiscal year, led by the Ankleshwar unit
Achieved EcoVadis Platinum Medal and operationalized 15.8 MW of solar power capacity
Portfolio expanded to over 610 chemistries with exports to more than 55 countries
Zero conflict-of-interest cases and zero POSH complaints reported for the year

💡 Investors should note the company's successful transition to its new identity and its strong ESG positioning which may attract institutional capital. The 25% capacity expansion and move into semiconductor chemicals provide a positive outlook for medium-term growth.

Acutaas Chemicals Q3 FY26 Net Profit Surges 139% YoY to ₹108.6 Cr; Revenue Up 42%

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 29 Jan 2026, 05:45 PM

Acutaas Chemicals (formerly Ami Organics) reported a stellar performance for Q3 FY26, with consolidated revenue growing 42.3% YoY to ₹391.2 crore. Net profit for the quarter witnessed a massive jump of 139% YoY, reaching ₹108.6 crore compared to ₹45.4 crore in the previous year. For the nine-month period, the company has already surpassed its full-year FY25 profit, recording ₹222.1 crore. The company also highlighted a strategic investment of ₹130.80 crore in its South Korean joint venture, Indichem Inc., to bolster its specialty chemicals portfolio.

Consolidated Revenue from operations rose 42.3% YoY to ₹39,118.33 Lakhs in Q3 FY26.
Net Profit surged by 139% YoY to ₹10,863.62 Lakhs, driven by strong operational efficiency.
Basic EPS for the quarter stood at ₹13.12, up from ₹5.42 in the corresponding quarter of the previous year.
The company invested ₹130.80 crore in South Korean JV Indichem Inc., holding a 75% stake through its subsidiary.
9-month consolidated profit reached ₹22,208.56 Lakhs, a 127% increase over the ₹9,770.16 Lakhs recorded in 9M FY25.

💡 The company is exhibiting robust earnings momentum and successful execution of its global expansion strategy. Investors should maintain a positive outlook while monitoring the integration of the South Korean JV and the impact of the newly granted ESOPs on future employee costs.

Acutaas Chemicals Releases Audio Recording of Earnings Call Held on January 28, 2026

🟡 NEUTRAL ⭐ 3/10

EARNINGS 📅 28 Jan 2026, 06:33 PM

Acutaas Chemicals Limited has officially released the audio recording of its earnings conference call conducted on January 28, 2026. The disclosure is made in compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, following the company's initial notification on January 22, 2026. The recording provides transparency regarding management's discussion on the company's financial performance and strategic outlook. Investors can access the full audio file via the company's investor relations website.

Earnings call was held on January 28, 2026, at 5:00 p.m. IST.
Recording link is available on the company website as per SEBI Regulation 30 and 46(2).
The filing follows a prior intimation regarding the call submitted on January 22, 2026.
The audio file is hosted at https://acutaas.com/static/uploadfiles/downloads/download_5812.mp3.

💡 Investors should listen to the recording to understand management's perspective on quarterly results and future growth guidance. This is a routine administrative filing and does not necessitate immediate portfolio changes.

Acutaas Chemicals Q3 FY26 PAT Surges 133.7% YoY to ₹1,062 Mn; Revenue Up 43%

🟢 POSITIVE ⭐ 9/10

EARNINGS 📅 28 Jan 2026, 03:11 PM

Acutaas Chemicals reported a stellar performance for Q3 FY26, with revenue growing 43% YoY to ₹3,932 million. The company achieved a significant milestone as quarterly PAT crossed ₹1,000 million for the first time, reaching ₹1,062 million. Profitability margins saw substantial expansion, with EBITDA margins jumping to 38.3% from 25.0% in the previous year. Management has also raised its full-year revenue growth guidance from 25% to approximately 30%, citing strong momentum in the CDMO business and upcoming verticals like battery and semiconductor chemicals.

Revenue from operations grew 43% YoY to ₹3,932 million, driven by the CDMO business ramp-up.
Net Profit (PAT) skyrocketed by 133.7% YoY to ₹1,062 million, crossing the ₹1,000 million quarterly milestone.
EBITDA margins expanded significantly by 1,330 bps YoY to reach 38.3% compared to 25.0% in Q3FY25.
Full-year revenue growth guidance revised upward from 25% to approximately 30% for FY26.
Gross margins improved to 57.0%, up 1,073 bps YoY, reflecting a superior product mix and operational efficiency.

💡 Investors should take note of the significant margin expansion and the management's confidence reflected in the upward guidance revision. The company's strategic pivot into semiconductor and battery chemicals offers strong long-term growth catalysts beyond its core pharmaceutical business.

View All ACUTAAS Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

The Pharmaceutical Intermediates segment grew 50% YoY to INR 854 Cr in FY25, while the Specialty Chemicals segment grew 2.2% YoY to INR 152.9 Cr. Total revenue for Q2 FY26 reached INR 306.2 Cr, representing a 24.1% YoY growth, and H1 FY26 revenue reached INR 513.4 Cr, a 21% increase.

Geographic Revenue Split

In FY25, exports accounted for 74% of total revenue, while the domestic business contributed 26%. The company has a widespread geographical presence across more than 55 countries.

Profitability Margins

Gross margin for Q2 FY26 was 55.8%, an expansion of 1,232 basis points YoY. PAT margin for Q2 FY26 was 23.5%, expanding by 824 basis points. FY25 PBILDT margin was 23.51%, up from 18.39% in FY24, driven by a shift in sales mix toward higher-margin products.

EBITDA Margin

EBITDA margin for Q2 FY26 was 31.1%, up 1,130 basis points YoY. The company has provided a guidance of 28% to 30% for FY26, driven by higher CDMO contribution and operational efficiencies.

Capital Expenditure

Gross Cash Accruals (GCA) doubled to INR 193.59 Cr in FY25 from INR 100.70 Cr in FY24, supporting internal funding of projects. Block 3 was commissioned in Q4 FY24 and is now operational to meet customer requirements.

Credit Rating & Borrowing

The company holds a CARE A+; Stable / CARE A1+ rating as of December 2025. Interest coverage is exceptionally strong at 119.86x for H1 FY26, with an overall gearing ratio of 0.01x as of September 30, 2025.

⚙️ Operational Drivers

Raw Materials

Key Starting Materials (KSM) and specific chemicals like VC and FEC for the electrolyte business; raw material costs represent approximately 72% of the total cost of sales.

Import Sources

Approximately 71% of raw materials are sourced domestically from India, while 21% are imported from China to ensure supply chain resilience.

Capacity Expansion

Block 3 was commissioned in Q4 FY24 for dedicated contracts. The company also operates a 6MW captive solar plant to drive energy efficiency. Electrolyte additive commercial operations have commenced with a ramp-up expected from FY26.

Raw Material Costs

Raw material costs account for 72% of total cost of sales. The company manages volatility by revising export prices quarterly based on KSM prices and using spot pricing for domestic sales.

Manufacturing Efficiency

The company is transitioning to Flow Chemistry to reduce solvent consumption and improve input-output efficiency. Operating leverage contributed to the 1,130 bps expansion in EBITDA margins in Q2 FY26.

📈 Strategic Growth

Expected Growth Rate

25%

Growth Strategy

Growth will be achieved through the ramp-up of the CDMO business, which saw sharp growth in Q2 FY26, and the commercialization of semiconductor chemicals through Baba Fine Chemicals. The company is also churning out low-margin products from its core pharma portfolio to improve margins while maintaining a 25% revenue growth target. New verticals like electrolyte additives are expected to contribute significantly from FY26 onwards.

Products & Services

Advanced pharmaceutical intermediates for regulated and generic APIs, New Chemical Entities (NCE), photo-resistant specialty chemicals, and electrolyte additives for batteries.

Brand Portfolio

Acutaas Chemicals (formerly Ami Organics), Baba Fine Chemicals, Indichem (Korea), and Acutaas Advance Material Limited.

New Products/Services

Semiconductor chemicals and electrolyte additives for batteries; electrolyte business has firm orders in hand for FY26 ramp-up.

Market Expansion

Expanding Baba Fine Chemicals into new geographies and diversifying the international footprint across 55+ countries to mitigate regional economic slowdowns.

Strategic Alliances

Acquisition of a non-controlling stake in Indichem (Korea) and the acquisition of Baba Fine Chemicals (now Acutaas Advance Material Limited).

🌍 External Factors

Industry Trends

The specialty chemicals industry is evolving toward sustainable processes like Flow Chemistry. Acutaas is positioning itself as a diversified player across pharma, semiconductors, and battery chemicals to capture a 31% historical CAGR trend.

Competitive Landscape

Faces intensifying competition in specialty chemicals which can affect pricing; responds through product differentiation and cost leadership.

Competitive Moat

Moat is built on R&D capabilities, a portfolio of 610+ products, and high switching costs for customers in the regulated pharma space. This is sustainable due to the long-term nature of CDMO contracts and stringent regulatory approvals.

Macro Economic Sensitivity

Sensitive to global pharmaceutical demand and semiconductor industry cycles; revenue is highly dependent on the 74% export market.

Consumer Behavior

Shift toward energy-efficient and environmentally friendly chemical processes is driving the adoption of Flow Chemistry.

Geopolitical Risks

Ongoing tensions could disrupt the 21% of raw materials sourced from China or impact the 74% export revenue across 55 countries.

⚖️ Regulatory & Governance

Industry Regulations

Operations are subject to strict regulatory standards for pharmaceutical intermediates and EHS protocols. Non-compliance could lead to operational disruptions.

Environmental Compliance

The company must adhere to stringent EHS regulations; it has invested in a 6MW solar plant and Flow Chemistry to meet environmental standards.

Taxation Policy Impact

Current tax provision for FY25 was INR 49.19 Cr on a consolidated basis.

⚠️ Risk Analysis

Key Uncertainties

Execution risk of ongoing projects and potential miscalculation of market demand for new verticals like semiconductors could impact profitability by 5-10%.